October 22, 2025

New York Regulators Target Omnium Health for Illicit Cannabis Sales

News Summary

New York state regulators have launched actions against Omnium Health Inc., alleging that the company has facilitated illicit cannabis sales through unlicensed products. The Office of Cannabis Management aims to impose severe penalties, potentially revoking licenses and imposing monetary fines exceeding $1 million. Investigations revealed Omnium’s controversial ‘rent-a-license’ practice, which allowed unlicensed operators to sell unauthorized cannabis items. Following the quarantine of $10 million worth of products, the OCM emphasizes this action as part of broader regulatory efforts to ensure compliance in the cannabis industry.

New York state regulators have initiated actions against Long Island-based Omnium Health Inc., a licensed processor and distributor of cannabis products, due to allegations of illicit operations. The state’s Office of Cannabis Management (OCM) claims that Omnium developed a scheme that allowed unlicensed products to be sold in licensed retailers, providing illicit operators with what is described as “an unearned backdoor” to the state’s lucrative $1.8 billion legal cannabis market.

Omnium is facing serious repercussions as the OCM has outlined the potential for monetary penalties in the seven-figure range and immediate revocation of its essential business permits. The agency is actively seeking remedies including the cancellation of Omnium’s processing and distribution licenses as well as preventing them from applying for future licensing.

Among the specific allegations, Omnium has reportedly been connected to a controversial practice termed “rent-a-license,” whereby it allegedly rented out its facilities to unlicensed operators. This would permit these operators to utilize Omnium’s license to distribute unauthorized cannabis products. The investigation into Omnium began in February 2025, during which OCM uncovered contracts between Omnium and various unlicensed entities.

The regulatory agency is pursuing a minimum fine of $1 million in relation to the unauthorized sale of cannabis products. Senarios have arisen where high-profile brands, such as Stiiizy and Mfused, were linked to Omnium’s operations, raising concerns that other brands may also be implicated in upcoming product recalls. In addition, the OCM has called for the recall and destruction of goods processed using Omnium’s facilities by unlicensed operators.

In April, the investigation led to the quarantine of approximately $10 million worth of cannabis products, including vaporizers and pre-rolls. Officials from the OCM stated that this enforcement action is just the beginning of a broader crackdown on violations within the cannabis industry.

The agency is also conducting investigations into other companies regarding similar compliance issues. Among these concerns is the practice of cannabis inversion, where illegal marijuana from out of state may be used in products that are marketed as legal within the state. Experts within the cannabis industry have welcomed these enforcement actions, emphasizing their importance for consumer safety and ensuring fair competition in the market.

This latest action against Omnium follows a previous case involving a testing laboratory known as Lexachrom, which was accused of falsifying results for cannabis product testing. Investigators have based their concerns on evidence indicating no proof that the THC isolate found at Omnium’s facilities was produced within the framework of the state’s regulated system.

As investigations and regulatory scrutiny continues, Omnium has not yet responded to media requests regarding the allegations. Meanwhile, OCM officials have indicated that ongoing investigations into various cannabis licensees will persist as part of a broader initiative to ensure compliance across New York’s cannabis industry.